OmniAb, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024, on March 18, 2025. For Q4 2024, total revenue was $10.8 million, an increase from $4.8 million in the same period of 2023, primarily driven by higher license and milestone revenue.
The company reported a net loss of $13.1 million, or $0.12 per share, for Q4 2024, compared to a net loss of $14.1 million, or $0.14 per share, in Q4 2023. For the full year 2024, total revenue was $26.4 million, a decrease from $34.2 million in 2023, mainly due to a $10.0 million TECVAYLI® milestone in 2023 and lower royalty revenue.
OmniAb's full year 2024 net loss was $62.0 million, or $0.61 per share, compared to $50.6 million, or $0.51 per share, in 2023. As of December 31, 2024, the company held $59.4 million in cash, cash equivalents, and short-term investments.
For 2025, OmniAb introduced revenue guidance in the range of $20 million to $25 million and operating expense guidance between $90 million and $95 million. The company also expects its 2025 cash use to be lower than the $38.9 million used in 2024, excluding ATM issuance.
Operationally, OmniAb ended 2024 with 91 active partners and 363 active programs, including 32 OmniAb-derived programs in clinical development or commercialization. The company signed 10 new license agreements in 2024 and saw five new OmniAb-derived antibodies enter clinical trials.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.